137
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Malignant mixed Müllerian tumours, also known as carcinosarcomas, are rare tumours of gynaecological origin. Here we perform whole-exome analyses of 22 tumours using massively parallel sequencing to determine the mutational landscape of this tumour type. On average, we identify 43 mutations per tumour, excluding four cases with a mutator phenotype that harboured inactivating mutations in mismatch repair genes. In addition to mutations in TP53 and KRAS, we identify genetic alterations in chromatin remodelling genes, ARID1A and ARID1B, in histone methyltransferase MLL3, in histone deacetylase modifier SPOP and in chromatin assembly factor BAZ1A, in nearly two thirds of cases. Alterations in genes with potential clinical utility are observed in more than three quarters of the cases and included members of the PI3-kinase and homologous DNA repair pathways. These findings highlight the importance of the dysregulation of chromatin remodelling in carcinosarcoma tumorigenesis and suggest new avenues for personalized therapy.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

          Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 mutations and mutations in other homologous recombination DNA repair genes is uncertain.
            • Record: found
            • Abstract: found
            • Article: not found

            FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.

            FBW7 (F-box and WD repeat domain-containing 7) is the substrate recognition component of an evolutionary conserved SCF (complex of SKP1, CUL1 and F-box protein)-type ubiquitin ligase. SCF(FBW7) degrades several proto-oncogenes that function in cellular growth and division pathways, including MYC, cyclin E, Notch and JUN. FBW7 is also a tumour suppressor, the regulatory network of which is perturbed in many human malignancies. Numerous cancer-associated mutations in FBW7 and its substrates have been identified, and loss of FBW7 function causes chromosomal instability and tumorigenesis. This Review focuses on structural and functional aspects of FBW7 and its role in the development of cancer.
              • Record: found
              • Abstract: found
              • Article: not found

              Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.

              The ability to study nonhematologic cancers through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven both by major technologic advances, including the isolation of intact cancer cells and the analysis of cancer cell-derived DNA from blood samples, and by the increasing application of molecularly driven therapeutics, which rely on such accurate and timely measurements of critical biomarkers. Moreover, the dramatic efficacy of these potent cancer therapies drives the selection for additional genetic changes as tumors acquire drug resistance, necessitating repeated sampling of cancer cells to adjust therapy in response to tumor evolution. Together, these advanced noninvasive diagnostic capabilities and their applications in guiding precision cancer therapies are poised to change the ways in which we select and monitor cancer treatments. Recent advances in technologies to analyze circulating tumor cells and circulating tumor DNA are setting the stage for real-time, noninvasive monitoring of cancer and providing novel insights into cancer evolution, invasion, and metastasis. ©2014 American Association for Cancer Research.

                Author and article information

                Journal
                101528555
                37539
                Nat Commun
                Nat Commun
                Nature communications
                2041-1723
                30 January 2015
                19 September 2014
                2014
                17 March 2015
                : 5
                : 5006
                Affiliations
                [1 ]Personal Genome Diagnostics, Baltimore, Maryland 21224, USA
                [2 ]Blueprint Medicines, Cambridge, Massachusetts 02142, USA
                [3 ]Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
                [4 ]Department of Pathology, Johns Hopkins University, Baltimore, Maryland 21287, USA
                [5 ]The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
                [6 ]Swim Across America Laboratory and the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, Baltimore, Maryland 21287, USA
                Author notes
                Correspondence and requests for materials should be addressed to C.L. ( clengauer@ 123456blueprintmedicines.com ) or to V.E.V. ( velculescu@ 123456jhmi.edu )
                [*]

                These authors contributed equally to this work.

                Article
                NIHMS658760
                10.1038/ncomms6006
                4354107
                25233892
                522d0646-e26c-4bda-bf03-3fe386a2778a
                © 2014 Macmillan Publishers Limited. All rights reserved.

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article

                Related Documents Log